BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9696800)

  • 1. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive.
    Tao Q; Robertson KD; Manns A; Hildesheim A; Ambinder RF
    J Virol; 1998 Sep; 72(9):7075-83. PubMed ID: 9696800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells.
    Paulson EJ; Fingeroth JD; Yates JL; Speck SH
    Virology; 2002 Jul; 299(1):109-21. PubMed ID: 12167346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.
    Bakos A; Banati F; Koroknai A; Takacs M; Salamon D; Minarovits-Kormuta S; Schwarzmann F; Wolf H; Niller HH; Minarovits J
    Virus Genes; 2007 Oct; 35(2):195-202. PubMed ID: 17510783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host cell-dependent expression of latent Epstein-Barr virus genomes: regulation by DNA methylation.
    Li H; Minarovits J
    Adv Cancer Res; 2003; 89():133-56. PubMed ID: 14587872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
    Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
    J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
    Schaefer BC; Strominger JL; Speck SH
    Mol Cell Biol; 1997 Jan; 17(1):364-77. PubMed ID: 8972217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.
    Schaefer BC; Paulson E; Strominger JL; Speck SH
    Mol Cell Biol; 1997 Feb; 17(2):873-86. PubMed ID: 9001242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection.
    Yoshioka M; Kikuta H; Ishiguro N; Ma X; Kobayashi K
    J Gen Virol; 2003 May; 84(Pt 5):1133-1140. PubMed ID: 12692278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of latent Epstein-Barr virus promoters.
    Takacs M; Banati F; Koroknai A; Segesdi J; Salamon D; Wolf H; Niller HH; Minarovits J
    Biochim Biophys Acta; 2010; 1799(3-4):228-35. PubMed ID: 19853674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
    J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
    Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
    J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.
    Chen H; Lee JM; Wang Y; Huang DP; Ambinder RF; Hayward SD
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):9339-44. PubMed ID: 10430944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection.
    Zetterberg H; Stenglein M; Jansson A; Ricksten A; Rymo L
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():457-466. PubMed ID: 10073708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
    Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
    J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTCF prevents the epigenetic drift of EBV latency promoter Qp.
    Tempera I; Wiedmer A; Dheekollu J; Lieberman PM
    PLoS Pathog; 2010 Aug; 6(8):e1001048. PubMed ID: 20730088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
    Schlager S; Speck SH; Woisetschläger M
    J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.
    Zhang L; Pagano JS
    J Virol; 2000 Feb; 74(3):1061-8. PubMed ID: 10627515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
    Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
    Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.
    Tierney RJ; Kirby HE; Nagra JK; Desmond J; Bell AI; Rickinson AB
    J Virol; 2000 Nov; 74(22):10468-79. PubMed ID: 11044091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro.
    Wang FW; Wu XR; Liu WJ; Liang YJ; Huang YF; Liao YJ; Shao CK; Zong YS; Mai SJ; Xie D
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):931-8. PubMed ID: 22146864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.